AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Vaccines & Immune Therapies / Infectious Disease by Year
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M) ($M)
AstraZeneca Vaccines & Immune Therapies / Infectious Disease: $220M in FY2025, up 3.3% from a year earlier.
Where the FY2025 figure comes from
“|| V&I | 846 | (20) | (20) | 209 | (26) | 220 | 3 | 5 | 354 | (13) | (15) | 63 | (60) | (60)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Therapy Area Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 220 | +3.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 213 | +0.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 212 | -83.9% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,316 | – | Form 6-K FY2022Q4 Earnings Release ↗ |
Breakdown
What makes up vaccines & Immune Therapies / Infectious Disease
Cite this data
StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease ($M), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-vi-em
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.